ACEIs and ARBs act on the renin–angiotensin–aldosterone system (RAAS) reducing angiotensin II formation and consequently downregulating ACE2 expression and probably reducing binding of SARS-COV-2 into the kidney cells and protecting against the development of AKI in COVID-19 patients. Here, ACE2 is linked to acute kidney injury.